## WST: West Pharmaceutical Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.3% below STRENGTH zone (3.0-6.0%); PEG 3.48 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($265.74)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Who Owns West Pharmaceutical Services? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260104T210935 | Neutral | Relevance: 100%
- This article examines the top institutional shareholders and recent insider trading activity of West Pharmaceutical Services (NYSE: WST). It highlights that institutional investors, particularly large asset managers and some hedge funds, hold significant stakes, suggesting long-term confidence in the company. Although insider trades were minimal, the overall ownership structure indicates a stable shareholder base with mixed views on current valuation.

**2. Investing in West Pharmaceutical Services (NYSE:WST) three years ago would have delivered you a 20% gain**
- Source: Simply Wall Street | 20260104T130811 | Somewhat-Bearish | Relevance: 100%
- West Pharmaceutical Services (NYSE:WST) shareholders have seen a 19% gain over the last three years, which lags behind the overall market return. The company's earnings per share have declined by 6.8% annually over the same period, suggesting that the share price movement isn't driven by EPS growth. Additionally, the stock has experienced an 18% decrease in the past year, indicating a recent downturn in performance.

**3. Ethic Inc. Purchases 4,206 Shares of West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20260103T070903 | Bullish | Relevance: 100%
- Ethic Inc. significantly increased its stake in West Pharmaceutical Services (NYSE:WST) by 200% in Q3, acquiring 4,206 additional shares, bringing its total holdings to 6,309 shares valued at approximately $1.655 million. West Pharmaceutical Services surpassed Q3 earnings and revenue estimates and provided positive FY2025 guidance. The company maintains a "Moderate Buy" consensus rating from analysts with an average target price of $342.20.

**4. Investing in West Pharmaceutical Services (NYSE:WST) three years ago would have delivered you a 20% gain**
- Source: Simply Wall Street | 20260104T125454 | Neutral | Relevance: 94%
- Over three years, West Pharmaceutical Services (NYSE:WST) shares gained 19%, underperforming the overall market. The company experienced a 6.8% annualized decrease in earnings per share over the same period, despite modest 0.7% revenue growth. While the stock is well-covered by analysts, its performance suggests fundamental challenges that warrant further investigation beyond basic metrics.

**5. Cynosure Group LLC Sells 5,293 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20260105T091145 | Neutral | Relevance: 60%
- Cynosure Group LLC significantly reduced its stake in Thermo Fisher Scientific Inc. ($TMO) by selling 5,293 shares, marking a 69.3% decrease in its holdings during the third quarter. This comes amidst substantial insider selling, with executives like EVP Frederick M. Lowery and CEO Marc N. Casper divesting shares totaling over $86.5 million in the past 90 days. Despite this, Thermo Fisher has announced a $5.0 billion stock buyback program, declared a $0.43 quarterly dividend, and exceeded quarterly earnings expectations, setting positive FY2025 guidance.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.12M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +1.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.48 signals overvaluation risk, limited margin of safety. Forward P/E 35.8x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $20.1B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.48 |
| Forward P/E | 35.8 |
| Current P/E | 39.3 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.2% to 1.3% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.7pp (needs >3.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.64), confirming momentum. RSI neutral at 57. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.28% (CS: 57) | Neutral |
| RSI_14 | 56.6 | Neutral |
| MACD Histogram | 0.64 | Bullish |
| vs SMA20 | 1.023x | Above |
| vs SMA50 | 1.014x | Above |
| vs SMA200 | 1.146x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $279.06
- **Stop Loss:** $265.74 (4.8% risk)
- **Target:** $292.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 64
- **Position Value:** $17,859.84
- **Portfolio %:** 17.86%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*